MSB Provides Q3 Financial Results and Operational Highlights
Filed with ASX · · 7 pages · English
In the deck
Story so far
Earlier from Mesoblast
- Mesoblast Initiates Rolling Submission of BLA for GvHD
- MoU for Confirmatory Trial for GI Bleeding in LVAD Patients
- MSB Licensee Files For Skin Disease Marketing Approval
- MSB Draws US$15 Million From Existing Facility
- P3 Trial of MSBs Cell Therapy in CHF Completes Recruitment
Later from Mesoblast
- MSB Expands JCR Partnership To Brain Disease In Newborns
- FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs
- Circulation Research Highlights MSB Heart Failure Therapy
- Appendix 4C - Quarterly, Strong Commercialization Revenues
- FDA Guidance on Clinical Pathway for LVAD Market Application
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast